Furthermore, there were no NPM1 mutations among 88 patients with KMT2Ar AML, and mutations in FLT3, IDH, and CEBPA were significantly less common when compared to diploid AML (Fig. 1C and Supplemental Fig. 2). This evidence concerns the gene CEBPA and acute myeloid leukemia.